文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

危重症患者一氧化氮抑制剂变化与死亡率:队列研究

Changes in nitric oxide inhibitors and mortality in critically ill patients: a cohort study.
PubMed 文献 · Ann Intensive Care · 2024-08-27
一句话结论ICU患者入ICU第1-3天ADMA浓度每日倍增与30天全因死亡率降低相关(HR 0.45),但入院时高ADMA/SDMA浓度与死亡率升高相关。

单中心队列研究纳入577例成人危重症患者,其中567例有第1-5天血浆样本,检测ADMA、SDMA、精氨酸和胍基丁胺(NO生物标志物)。第1-5天ADMA和精氨酸浓度升高;SDMA第1-2天升高后第2-5天下降;胍基丁胺第1-3天无变化,第3-5天轻度升高。512例患者入ICU 3天后存活,其中第1-3天ADMA浓度每日倍增与30天全因死亡率降低独立相关(HR 0.45;95%CI 0.21-0.98;p=0.046);SDMA、精氨酸或胍基丁胺升高与死亡率无关。事后分析显示入院时ADMA或SDMA浓度倍增与死亡率相关(HR 1.78;95%CI 1.24-2.57;p=0.0025;HR 1.41;95%CI 1.05-1.90;p=0.024)。作者建议未来研究应聚焦入院时ADMA/SDMA浓度作为死亡率预测因子或潜在治疗靶点。

要点

  • 第1-3天ADMA浓度每日倍增与30天全因死亡率降低相关(HR 0.45;95%CI 0.21-0.98;p=0.046),多因素分析。
  • 入院时ADMA浓度倍增与死亡率升高相关(HR 1.78;95%CI 1.24-2.57;p=0.0025)。
  • 入院时SDMA浓度倍增与死亡率升高相关(HR 1.41;95%CI 1.05-1.90;p=0.024)。
  • 第1-3天SDMA、精氨酸或胍基丁胺升高与死亡率无显著关联。
  • ADMA和精氨酸浓度第1-5天升高;SDMA第1-2天升高后第2-5天下降;胍基丁胺第1-3天无变化、第3-5天轻度升高。

适用人群与场景

  • 成人危重症患者,来自哥本哈根大学医院—北西兰岛ICU(单中心)。
  • 共577例患者纳入,其中567例有第1-5天血浆样本;512例入ICU 3天后存活并纳入第1-3天变化与死亡率分析。

研究设计与关键结果

  • 单中心队列研究,577例成人危重症患者,567例有第1-5天血浆样本;检测ADMA、SDMA、精氨酸和胍基丁胺。
  • 第1-5天ADMA和精氨酸浓度升高;SDMA第1-2天升高、第2-5天下降;胍基丁胺第1-3天无变化、第3-5天轻度升高。
  • 512例入ICU 3天后存活患者中,第1-3天ADMA浓度每日倍增与30天全因死亡率降低相关(多因素分析HR 0.45;95%CI 0.21-0.98;p=0.046)。
  • 第1-3天SDMA、精氨酸或胍基丁胺升高与死亡率无显著关联。
  • 事后分析:入院时ADMA浓度倍增与死亡率相关(HR 1.78;95%CI 1.24-2.57;p=0.0025);入院时SDMA浓度倍增与死亡率相关(HR 1.41;95%CI 1.05-1.90;p=0.024)。

证据类型、等级与局限

  • 证据类型:单中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者建议未来研究应聚焦入院时ADMA和SDMA浓度作为ICU患者死亡率预测因子或潜在治疗靶点。
  • 第1-3天ADMA浓度升高与死亡率降低的关联强度不如入院时高ADMA或SDMA浓度与死亡率升高的关联。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Optimal balance between macro- and microcirculation in critically ill patients is crucial for ensuring optimal organ perfusion. Nitric oxide (NO) is a regulator of vascular hemostasis and tone. The availability of NO is controlled by asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and the availability of the NO substrates arginine and homoarginine. We investigated the changes in plasma concentrations of ADMA, SDMA, arginine, and homoarginine days 1-5 of intensive care unit (ICU) admission and the association between the change in concentration days 1-3 and 30-day all-cause mortality.

METHODS: Single-center cohort study of adult critically ill patients from the ICU at Copenhagen University Hospital - North Zealand. ADMA, SDMA, arginine, and homoarginine (NO-biomarkers) were measured on days 1-5. Initially, we determined the changes in NO-biomarkers days 1-5 with linear mixed models, and subsequently how the changes in NO-biomarkers days 1-3 were associated with 30-day all-cause mortality. Post-hoc we analyzed the association between plasma concentration at admission and 30-day all-cause mortality.

RESULTS: In total 567 out of 577 patients had plasma samples from days 1-5. Plasma concentrations of ADMA and arginine increased from days 1-5. SDMA concentrations increased from days 1-2, followed by a decrease from days 2-5. Concentrations of homoarginine did not change from days 1-3 but slightly increased from days 3-5. In total 512 patients were alive 3 days after ICU admission. Among these patients, a daily twofold increase in ADMA concentration from days 1-3 was associated with decreased mortality in multivariate analysis (HR 0.45; 95% CI 0.21-0.98; p = 0.046). An increase in SDMA, arginine, or homoarginine was not associated with mortality. Post-hoc we found that a twofold increase in ADMA or SDMA concentrations at admission was associated with mortality (HR 1.78; 95% CI 1.24-2.57; p = 0.0025, and HR 1.41; 95% CI 1.05-1.90; p = 0.024, respectively).

CONCLUSIONS: Increasing ADMA concentrations on days 1-3 are inversely associated with mortality, however not with the same strength as high ADMA or SDMA concentrations at admission. We suggest that admission concentrations are the focus of future research on ADMA and SDMA as predictors of mortality or potential therapeutical targets in ICU patients.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Mortensen KM, Itenov TS, Stensballe J, et al. Changes in nitric oxide inhibitors and mortality in critically ill patients: a cohort study. Ann Intensive Care. 2024. PMID: 39190083. doi:10.1186/s13613-024-01362-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。